- Deepinder Goyal's Temple claims to have discovered a new biomarker called 'Entropy' that measures the body's real-time metabolic cost of being alive.
- The Entropy metric updates every second and is designed to track energy expenditure continuously.
- Goyal stated that the live metric displays scores ranging from 1 to 250, with lower values indicating deeper states of rest and higher values representing periods of intense physical output.
- Doctors have raised concerns about the claims, stating that the biomarker's validity remains unproven without methodology, validation studies, and peer-reviewed evidence.
- Critics, including Dr. Suvrankar Datta, have described Temple's offering as a 'fancy toy for billionaires' with 'zero scientific standing' as a medical instrument.
- According to Goyal, the Entropy score reflects changes in metabolism and the body's energy expenditure in real time.
- Goyal has committed $25 million from his personal wealth to expand his longevity venture, Continue Research, which aims to explore ways to extend human life.
- The project focuses on research related to ageing, nutrition, sleep, and mental wellness.
- Temple claims that various factors such as sleep, stress, exercise, food, caffeine, meditation, and even cold-water exposure influence the Entropy score.
Deepinder Goyal's neurotech startup Temple has introduced a new biomarker called Entropy, which measures the body's real-time metabolic cost. This metric updates every second and is designed to track energy expenditure continuously, with scores ranging from 1 to 250.12367
Goyal described Entropy as a live score displayed on the home screen, where lower values indicate deeper states of rest, recorded in meditators, while higher values represent intense physical output. “We have discovered (literally discovered) a biomarker, only readable on the temple region, and nowhere else,” Goyal stated.
Despite the excitement, the scientific community remains skeptical. Dr. Suvrankar Datta criticized the device as a “fancy toy for billionaires” with “zero scientific standing” as a medical instrument. Dr. Sudhir Kumar echoed these concerns, stating that the evidence presented so far is preliminary and does not validate Entropy as a biomarker for metabolism or health.5
Temple has opened applications for early access but has not disclosed a launch timeline or pricing. Goyal committed $25 million from his personal wealth to expand his longevity venture, Continue Research, which aims to explore ways to extend human life through research on aging, nutrition, and wellness. “Extraordinary claims require extraordinary evidence,” Dr. Kumar emphasized, highlighting the need for rigorous validation before public release.
Temple has promised to publish internal whitepapers and submit studies for peer review before launching the device.
“Deepinder Goyal's startup Temple has introduced a new biomarker called 'Entropy' that tracks the body's real-time energy expenditure. However, the scientific community expresses skepticism regarding its validation and accuracy.”
Inshorts